Practical Reviews

Primary Care Physician Awareness and Adoption of PrEP

Background: HIV pre-exposure prophylaxis (PrEP) is a medication-based HIV prevention strategy for HIV-negative persons. In 2014, the Centers for Disease Control and Prevention (CDC) issued guidelines for prescribing PrEP (tenofovir/emtricitabine) to persons at high HIV risk. The CDC estimates there are 1.2-million persons eligible for PrEP. However, since 2012 (when tenofovir/emtricitabine was approved for this indication), only about 80,000 people have been prescribed PrEP. Object more...
To view this content, you must be a logged in subscriber to
Please Login to view this content.